Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
CH1330780979
Thu, 12.09.2024
Curatis Holding AG
Curatis Holding AG
/ Key word(s): Miscellaneous
Teilnahme an der Investora am 19. September 2024 und frühere Publikation des Halbjahresreports am 16. September
12.09.2024 / 19:46 CET/CEST
MEDIA RELEASE
Liestal, Schweiz, 12. September 2024: Curatis Holding (SIX:CURN), ein Pharmaunternehmen mit Fokus auf Orphan Drugs und [ … ]
Thu, 12.09.2024
Curatis Holding AG
Curatis Holding AG
/ Key word(s): Miscellaneous
Teilnahme an der Investora am 19. September 2024 und frühere Publikation des Halbjahresreports am 16. September
12.09.2024 / 19:46 CET/CEST
MEDIA RELEASE
Liestal, Schweiz, 12. September 2024: Curatis Holding (SIX:CURN), ein Pharmaunternehmen mit Fokus auf Orphan Drugs und [ … ]
Tue, 27.08.2024
Curatis Holding AG
Curatis Holding AG
/ Key word(s): Expansion/Strategic Company Decision
Curatis auf Kurs: Einreichung des Antrags für Orphan-Drug-Designation des wichtigsten Produktkandidaten in den USA
27.08.2024 / 17:45 CET/CEST
MEDIA RELEASE
Liestal, Schweiz, 27. August 2024: Curatis Holding (SIX:CURN) hat bei der US-Medikamentenbehö [ … ]
Thu, 25.07.2024
Curatis Holding AG
Curatis Holding AG
/ Key word(s): Research Update
Curatis Holding AG: Initiation of Coverage and Publication of Equity Research Report by valuationLAB
25.07.2024 / 07:00 CET/CEST
MEDIA RELEASE
Curatis Holding (SIX:CURN) announces that the life science research company valuationLAB has initiated coverage and has issued a [ … ]
Fri, 21.06.2024
Curatis Holding AG
Curatis Holding AG
/ Key word(s): AGMEGM
Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors
21.06.2024 / 17:13 CET/CEST
MEDIA RELEASE
Liestal, Switzerland, 21 June 2024: Curatis Holding AG (CURN.SW), a SIX Swiss Exchange listed specialty pharmaceutical and therapeutic drug deve [ … ]